The global phage therapy market is undergoing a decisive transition from compassionate-use experimentation to a structured, regulatory-compliant biotherapeutic vertical. Our proprietary primary research and expert interview program estimates the market at USD 1.34 billion in 2026, with a projected expansion to USD 1.92 billion by 2035, representing a CAGR of 4.06% over the forecast period. This valuation reflects the commercial maturation of lytic and engineered bacteriophage platforms, which are now supported by purpose-built GMP manufacturing infrastructure and clearer regulatory designations in key jurisdictions.

The market narrative is no longer defined solely by the antimicrobial resistance (AMR) crisis; it is increasingly shaped by precision-microbiome medicine, synthetic biology-enabled designer phages, and the establishment of national phage banks. More than 90 active interventional clinical studies were registered globally in 2024, and investor confidence remains resilient, evidenced by the USD 50 million capital injection accompanying BiomX's acquisition of Adaptive Phage Therapeutics. These developments establish a disciplined yet expanding growth trajectory for an industry that is fundamentally redefining the treatment paradigm for multidrug-resistant (MDR) bacterial infections.

The phage therapy market is propelled by a confluence of clinical, regulatory, and technological factors, offset by structural bottlenecks that require strategic navigation.

Key Growth Drivers:

• Escalating MDR Infection Burden: The World Health Organization (WHO) projects drug-resistant infections could cause 10 million deaths annually by 2050. The clinical urgency is particularly acute for ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), where conventional antibiotics are increasingly ineffective.
• Expansion of Clinical Pipelines and Funding: The pipeline has broadened beyond academic studies into Phase 2 and Phase 3 assets. BARDA's USD 23.9 million award to Locus Biosciences for a CRISPR-engineered phage therapeutic (LBP-EC01) exemplifies the shift toward high-value, government-backed clinical development.
• Synthetic Biology and AI-Enabled Phage Selection: Advances in CRISPR-Cas3 genome shredding, high-throughput genome editing, and predictive phage-host matching are compressing discovery timelines and broadening bacterial coverage, making personalized phage therapy commercially viable.
• Supportive Regulatory Designations: The U.S. FDA's Breakthrough Therapy and Orphan Drug designations, alongside Belgium's magistral preparation framework, are creating clearer pathways for market entry and reimbursement.

Key Restraints:

• Heterogeneous Global Regulatory Frameworks: Divergent classifications across the EU (where phages are often treated as Advanced Therapy Medicinal Products) and the U.S. (where IND filings are required) increase development costs and delay multi-regional commercialization.
• Limited GMP Manufacturing Capacity: Traditional biologics plants are not designed for rapid, patient-specific phage runs. Sterility testing and process changeovers can exceed the clinical treatment window, causing supply delays.
• Emergence of Phage-Resistant Bacterial Mutants: The co-evolution of bacteria and phages necessitates continuous phage library updates and the use of cocktails to reduce resistance development.

The market's segmental composition reveals a strong preference for targeted, precision-oriented modalities, with significant growth opportunities in engineered and combination products.

By Product Type:

• Monophage Therapy dominates with a 42.2% share in 2026, driven by its high specificity and favorable safety profile. Companies such as PhageTech and Intralytix are advancing monophage assets for antibiotic-resistant infections.
• Phage Cocktails followed closely in 2025, capturing 35.78% of global revenue, as cocktails offer broader coverage and reduce the likelihood of resistance.
• Engineered/Recombinant Phages represent the fastest-growing product segment, fueled by synthetic biology platforms that enhance lytic activity and host range.
• Phage-Derived Enzymes (e.g., endolysins) and Combination Products (phage + antibiotic) are emerging as high-value niches, particularly for biofilm-associated infections.

By Target Pathogen:

• Gram-Negative Bacteria account for 56.7% of the market in 2026, reflecting the urgent clinical need to combat complex pathogens like E. coli, P. aeruginosa, and K. pneumoniae.
• Pseudomonas aeruginosa held a 26.88% share of the phage therapy market in 2025, while Klebsiella pneumoniae is projected to expand at a 6.02% CAGR through 2031.
• Gram-Positive Bacteria (e.g., S. aureus, including MRSA) remain a significant segment, particularly for skin and wound infections.

By Disease Indication:

• Urinary Tract Infections (UTIs) represent the largest indication segment, capturing 33.4% of the market in 2026, driven by the high prevalence of uropathogenic E. coli and rising antibiotic resistance.
• Respiratory Tract Infections (including Cystic Fibrosis) held 26.31% of the market in 2025 and continue to grow at 6.05% through 2031.
• Skin and Wound Infections, Bone and Joint Infections, and Biofilm-Related Chronic Infections are also key indication segments, with chronic wound care driving adoption.

By Route of Administration:

• Injectable/Intravenous routes commanded 44.63% of the market in 2025, essential for systemic infections.
• Oral administration is the largest segment by value in some segments, preferred for gastrointestinal and systemic delivery.
• Inhalation/Nebulized approaches are advancing at a 6.18% CAGR to 2031, particularly for cystic fibrosis and ventilator-associated pneumonia.

The geographic distribution of the phage therapy market reflects disparities in regulatory maturity, healthcare infrastructure, and research funding.

• North America dominates with 36% of global market share in 2025, underpinned by a robust clinical pipeline, favorable FDA designations, and significant venture capital investment. The U.S. accounts for the majority of regional revenue.
• Europe is the second-largest market, contributing 29% of global revenue. The region benefits from established phage banks (e.g., the UK Citizen Phage Library), compassionate-use networks (e.g., the Israeli Phage Therapy Center), and academic-industry collaborations. Germany, the UK, and Belgium are key markets.
• Asia-Pacific is the fastest-growing region, with a CAGR of 6.6% projected to 2031. The region's growth is driven by rising AMR awareness, expanding healthcare expenditure, and government-backed initiatives in China, India, and South Korea. South Korea has already established a purpose-built GMP facility for phage manufacturing.
• Latin America and Middle East & Africa represent emerging frontiers, with growth constrained by limited GMP capacity and heterogeneous regulatory pathways, but offering long-term opportunities as AMR burden intensifies.

The phage therapy market is characterized by a medium level of concentration, with a mix of clinical-stage biotechs, established diagnostics players, and academic spin-outs. Strategic activity has intensified as companies seek to consolidate pipelines and secure manufacturing capabilities.

Key Players:

• Armata Pharmaceuticals (U.S.) – Focused on P. aeruginosa and S. aureus infections; received USD 25 million from Innoviva in July 2023.
• Locus Biosciences (U.S.) – Pioneer in CRISPR-engineered phage therapeutics; BARDA awarded USD 23.9 million for its Phase 2 trial of LBP-EC01.
• BiomX (Israel/U.S.) – Acquired Adaptive Phage Therapeutics in March 2024, adding two Phase 2 assets and USD 50 million in capital.
• Intralytix (U.S.) – A leading player in monophage therapy and food safety applications.
• Pherecydes Pharma (France) – Specializes in phage cocktails targeting P. aeruginosa and S. aureus; entered research collaboration with the Laboratory of Molecular Microbiology and Structural Biochemistry in 2022.
• Eliava Biopreparations (Georgia) – A historic center for phage therapy, offering a range of commercial phage products.
• Phagelux (Canada/China) – Developing phage-based products for agriculture and human health.

Recent Strategic Developments:

• March 2024: BiomX completed the acquisition of Adaptive Phage Therapeutics, consolidating their clinical pipelines and securing USD 50 million in funding.
• July 2023: Armata Pharmaceuticals received USD 25 million in new financing from Innoviva to advance its therapeutic phage candidates.
• September 2022: Pherecydes Pharma entered a research collaboration to discover and characterize new lytic bacteriophages.

The phage therapy value chain encompasses phage discovery, characterization, manufacturing, formulation, and distribution. Each stage presents distinct challenges and opportunities.

• Discovery and Characterization: Involves isolating phages from environmental samples (e.g., sewage, soil) using host bacteria. Phage banks and bioinformatics platforms (e.g., genome sequencing, host-range prediction) are critical for rapid screening. The UK Citizen Phage Library can isolate clinically relevant phages within four days, streamlining emergency responses.
• Manufacturing: The transition from lab-scale to GMP-grade production is a major bottleneck. Traditional biologics plants are designed for large, uniform batches, whereas phage therapy often requires patient-specific, rapid runs. Purpose-built GMP sites in Belgium, South Korea, and the U.S. are beginning to address this gap, but capacity remains limited.
• Formulation and Delivery: Innovations in room-temperature storage (e.g., McMaster University's technology) and inhalation devices are expanding distribution and administration options. Lyophilization and encapsulation technologies are improving stability and shelf-life.
• Distribution and Reimbursement: Compassionate-use networks and national phage banks facilitate access in Europe and North America. However, uncertain reimbursement models and intellectual property frameworks continue to pose commercial risks, particularly for personalized phage preparations.

Despite robust growth, significant white spaces remain for investors and industry incumbents.

• Engineered Phages and Combination Products: The engineered/recombinant phage segment is poised for rapid growth, with applications in biofilm disruption and MDR infections. Combination products (phage + antibiotic) offer synergistic potential and may accelerate regulatory approval by leveraging existing antibiotic efficacy data.
• Veterinary and Agricultural Applications: Beyond human health, phage therapy is gaining traction in animal health, food safety, and aquaculture. The food safety and agriculture segment is projected to grow at the fastest rate, providing diversification and revenue streams outside human clinical trials.
• Point-of-Care Diagnostics and Personalized Phage Matching: The integration of rapid diagnostics with phage libraries can enable personalized therapy within 48-72 hours, a critical capability for chronic and refractory infections. Companies investing in AI-driven phage-host matching and high-throughput screening are positioned to capture this high-value niche.
• Emerging Markets: Asia-Pacific, particularly China and India, represent untapped potential for phage therapy adoption, driven by high AMR burden and growing healthcare infrastructure. Strategic partnerships with local manufacturers and research institutions can facilitate market entry.

In conclusion, the phage therapy market is on a trajectory of disciplined expansion, underpinned by clinical validation, regulatory progress, and technological innovation. Stakeholders who navigate manufacturing and regulatory complexities while investing in engineered modalities and emerging geographies will be well-positioned to capitalize on this evolving post-antibiotic paradigm.